What’s it like reporting on the FDA during the early and turbulent weeks of the Trump administration? Why did Bluebird Bio ...
Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback